ALSO NOTED: Paion inks $102M deal; Sepracor chairman plans retirement years;and much more...

> Sepracor Chairman Timothy Barberich is planning to retire. He will receive $1.65 million a year under a retirement pact. Report

> After being abandoned by Forest Laboratories, Germany's Paion has inked a $102 million development deal for the stroke drug desmoteplase. Release

> Forest Labs and Cypress Biosciences have submitted an NDA for milnacipran for fibromyalgia syndrome. Release

> The UK's Axa Framlington Health says the threat of an economic slowdown has not hampered its investment strategy in biotech. Report

> The CEO of Charles River Laboratories has exercised his options for 30,000 shares of common stock. Report

And Finally… We weren't the only ones to take a look back at 2007. Here's the Guardian's take on the year past. Article